Roche is try­ing again and again in Alzheimer’s. This time, ear­ly da­ta are ‘worth watch­ing’

Years of Alzheimer’s set­backs have not dis­suad­ed Roche from go­ing af­ter one of the most chal­leng­ing R&D fields, and new da­ta in­di­cate how its con­tin­ued ef­forts could ul­ti­mate­ly pay off.

At a med­ical con­fer­ence Sat­ur­day, Roche pre­sent­ed new Phase Ib/IIa da­ta for high-dose tron­tinemab, an amy­loid-tar­get­ing an­ti­body. The re­sults are very ear­ly: Roche had ef­fi­ca­cy da­ta from eight pa­tients at an in­ter­im 12-week fol­low-up.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER